Federal Register / Vol. 60, No. 85 / Wednesday, May 3, 1995 / Notices 21823

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 041095 AND 042195—Continued

Name of acquiring person, name of acquired person, name of acquired entity PMN No. Date terminated

Arch Communications Group, Inc., USA Mobile Communications Holdings, Inc., USA Mobile Communications

Holdings, Inc. ........................................................................................................................................................ 95–1420 04/21/95

Citizens, Inc., American Liberty Financial Corporation, American Liberty Financial Corporation .......................... 95–1433 04/21/95

Living Centers of America, Inc., Mr. Donald C. Beaver, see attached list ............................................................. 95–1435 04/21/95

Mr. Donald C. Beaver, Living Centers of American, Inc. Living Centers of America, Inc. ..................................... 95–1436 04/21/95

Akzo Nobel nv, BASF Aktiengesellschaft (‘‘BASF AG’’), BASF Corporation .......................................................... 95–1437 04/21/95

The Dow Chemical Company, Oasis Piple Line Company, Oasis Pipe Line Company ........................................ 95–1440 04/21/95

Egyptian General Petroleum Corporation, Mosvold Shipping AS, Seadrill 97, Inc. ............................................... 95–1441 04/21/95

Coastal Healthcare Group, Inc., Mid-South Insurance Company, Mid-South Insurance Company ....................... 95–1442 04/21/95

Oxford Health Plans, Inc., OakTree Health Plan, Inc., OakTree Health Plan, Inc. ................................................ 95–1443 04/21/95

Tiger (a limited partnership), XTRA Corporation, XTRA Corporation ..................................................................... 95–1444 04/21/95

Panther Partners L.P., XTRA Corporation, XTRA Corporation ............................................................................... 95–1445 04/21/95

Puma (a limited partnership), EXTRA Corporation, XTRA Corporation ................................................................. 95–1446 04/21/95

USA Mobile Communications Holdings, Inc., Arch Communications Group, Inc., Arch Communications Group,

Inc. ........................................................................................................................................................................ 95–1447 04/21/95

ABC Rail Products Corporation, General Electric Corp., GE Railcar Wheel .......................................................... 95–1448 04/21/95

AMP Incorporated, M/A-Com, Inc., M/A-Com, Inc. ................................................................................................. 95–1449 04/21/95

The Jaguar Fund N.V., XTRA Corporation, XTRA Corporation .............................................................................. 95–1450 04/21/95

Union Pacific Corporation, Robert M. Edsel, Gemini Exploration Company .......................................................... 95–1451 04/21/95

International Reality Investors, L.L.C., Bramalea Inc., Colonial Park Mall ............................................................. 95–1454 04/21/95

RIT Capital Partners PLC, Mr. David Elias, H-G Holdings, Inc. ............................................................................. 95–1456 04/21/95

The Coastal Corporation, Cohyco, Inc., Maverick Markets, Inc. ............................................................................. 95–1457 04/21/95

Golder, Thoma, Cressey, Rauner Fund IV, L.P., Kwik-Wash Laundries, Inc., Ford Coin Laundries, Inc. ............. 95–1458 04/21/95

Kelso Investment Associates V, L.P., Peebles Inc., Peebles Inc. .......................................................................... 95–1459 04/21/95

Converse Inc., Apex One, Inc., Apex One, Inc. ...................................................................................................... 95–1461 04/21/95

Code, Hennessy & Simmons II, L.P., Home-Crest Corporation, Home-Crest Corporation .................................... 95–1462 04/21/95

Elcat, Inc., Chattem, Inc., Chattem Chemicals Divsion ........................................................................................... 95–1465 04/21/95

Roland O. Perelman, Stephen J. Cannell, Cannell Entertainment, Inc. ................................................................. 95–1470 04/21/95

Clal (Israel) Ltd., Pharmaceutical Resources, Inc., Pharmaceutical Resources, Inc. ............................................. 95–1471 04/21/95

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton,

Contact Representatives, Federal Trade

Commission, Premerger Notification

Office, Bureau of Competition, room

303, Washington, DC 20580 (202) 326–

3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95–10885 Filed 5–2–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0108]

Drug Export; VAQTATM Hepatitis A

Vaccine, Purified Inactivated

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Merck & Co., Inc., has filed an

application requesting approval for the

export of the final bulk human

biological product VAQTATM Hepatitis

A Vaccine, Purified Inactivated to the

Federal Republic of Germany and The

United Kingdom.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

human biological products under the

Drug Export Amendments Act of 1986

should also be directed to the contact

person.

FOR FURTHER INFORMATION CONTACT:

Cathy Conn, Center for Biologics

Evaluation and Research (HFM–610),

Food and Drug Administration, 1401

Rockville Pike, Rockville, MD 20852–

1448, 301–594–1070.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of biological products that are

not currently approved in the United

States. Section 802(b)(3)(B) of the act

sets forth the requirements that must be

met in an application for approval.

Section 802(b)(3)(C) of the act requires

that the agency review the application

within 30 days of its filing to determine

whether the requirements of section

802(b)(3)(B) have been satisfied. Section

802(b)(3)(A) of the act requires that the

agency publish a notice in the Federal

Register within 10 days of the filing of

an application for export to facilitate

public participation in its review of the

application. To meet this requirement,

the agency is providing notice that

Merck & Co., Inc., P.O. Box 4, West

Point, PA 19486, has filed an

application requesting approval for the

export of the final bulk human

biological product VAQTATM Hepatitis

A Vaccine, Purified Inactivated, to the

United Kingdom for filling into syringes

and export to the Federal Republic of

Germany and the United Kingdom. The

VAQTATM Hepatitis A Vaccine, Purified

Inactivated, is a highly purified

inactivated whole virus vaccine derived

from hepatitis A virus grown in cell

culture in human fibroblasts. The

application was received and filed in

the Center for Biologics Evaluation and

Research on February 13, 1995, which

shall be considered the filing date for

purposes of the act.

Interested persons may submit

relevant information on the application

to the Dockets Management Branch

(address above) in two copies (except

that individuals may submit single

copies) and identified with the docket

number found in brackets in the

heading of this document. These

submissions may be seen in the Dockets
21824 Federal Register / Vol. 60, No. 85 / Wednesday, May 3, 1995 / Notices

Management Branch between 9 a.m. and

4 p.m., Monday through Friday.

The agency encourages any person

who submits relevant information on

the application to do so by May 15,

1995, and to provide an additional copy

of the submission directly to the contact

person identified above, to facilitate

consideration of the information during

the 30-day review period.

This notice is issued under the

Federal Food, Drug, and Cosmetic Act

(sec. 802 (21 U.S.C. 382)) and under

authority delegated to the Commissioner

of Food and Drugs (21 CFR 5.10) and

redelegated to the Center for Biologics

Evaluation and Research (21 CFR 5.44).

Dated: April 12, 1995.

James C. Simmons,

Acting Director, Office of Compliance, Center

for Biologics Evaluation and Research.

[FR Doc. 95–10898 Filed 5–2–95; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[HSQ–227–N]

Medicare Program; Peer Review

Organization Contracts: Solicitation of

Statements of Interest From In-State

Organizations—Alaska, Delaware, the

District of Columbia, Idaho, Kentucky,

Maine, Nebraska, Nevada, South

Carolina, Vermont, and Wyoming

AGENCY: Health Care Financing

Administration (HCFA), HHS.

ACTION: General notice.

SUMMARY: This notice, in accordance

with section 1153(i) of the Social

Security Act, announces the scheduled

expiration dates of the current contracts

between HCFA and several out-of-State

Utilization and Quality Control Peer

Review Organizations. It also specifies

the period of time in which in-State

organizations may submit a statement of

interest so that they may be eligible to

compete for these contracts. The States

currently affected and their respective

expiration dates are as follows:

Delaware ........................... March 31, 1996.

Nevada .............................. March 31, 1996.

Wyoming ........................... March 31, 1996.

Alaska ............................... June 30, 1996.

District of Columbia ......... June 30, 1996.

Idaho ................................. June 30, 1996.

Maine ................................ June 30, 1996.

Vermont ............................ June 30, 1996.

Nebraska ........................... September 30,

1996.

Kentucky ........................... September 30,

1996.

South Carolina .................. September 30,

1996.

DATES: Written statements of interest

must be received at the address

specified no later than 5 p.m. EST, June

2, 1995. Due to staffing and resource

limitations, we cannot accept statements

submitted by facsimile (FAX)

transmission.

ADDRESSES: Statements of interest must

be submitted to—Health Care Financing

Administration, OFHR, OAG, Attn.:

Brian Hebbel, Room G–M–1, East Low

Rise Building, 6325 Security Boulevard,

Baltimore, Maryland 21207.

FOR FURTHER INFORMATION CONTACT:

Kathleen Kelso, (410) 966–7214.

SUPPLEMENTARY INFORMATION:

I. Background

The Peer Review Improvement Act of

1982 (Title I, Subtitle C of the Tax

Equity and Fiscal Responsibility Act of

1982 (TEFRA), Pub. L. 97–248)

amended Part B of Title XI of the Social

Security Act (the Act) by establishing

the Utilization and Quality Control Peer

Review Organization (PRO) program.

Congress created the PRO program in

order to redirect, simplify, and enhance

the cost-effectiveness and efficiency of

the peer review process.

PROs currently review certain health

care services furnished under Title

XVIII of the Act (Medicare) and under

certain other Federal programs to

determine whether those services are

reasonable, medically necessary,

furnished in the appropriate setting, and

are of a quality that meets professionally

recognized standards. PRO activities are

a part of the Health Care Quality

Improvement Program (HCQIP) that

supports HCFA’s mission of assuring

health care security for its eligible

beneficiaries. The HCQIP is carried out

locally by the PRO in each State. Under

the HCQIP, PROs provide information

for health care plans, providers, and

practitioners to improve the quality of

care furnished to Medicare

beneficiaries.

In June 1984, HCFA began awarding

contracts to PROs. We currently

maintain 53 PRO contracts with

organizations that provide medical

review activities for 49 of the United

States, the District of Columbia, Puerto

Rico, and the Virgin Islands. The

organizations that are eligible to

contract as PROs have satisfactorily

demonstrated that they are either

physician-sponsored or physicianaccess organizations in accordance with

sections 1152 and 1153 of the Act and

our regulations at 42 CFR 462.102 and

462.103. A physician-sponsored

organization is one that is both

composed of a substantial number of the

licensed doctors of medicine or

osteopathy practicing medicine or

surgery in the respective review area

and is representative of the physicians

practicing in the review area. A

physician-access organization is one

that has available to it, by arrangement

or otherwise, the services of a sufficient

number of licensed doctors of medicine

or osteopathy practicing medicine or

surgery in the review area to assure

adequate peer review of the services

furnished by the various medical

specialties and subspecialties. In

addition, the organization must not be a

health care facility, health care facility

association, or a health care facility

affiliate, and must have a consumer

representative on its governing board.

The Omnibus Budget Reconciliation

Act of 1987 (Pub. L. 100–203) amended

section 1153 of the Act by adding a new

subsection (i) that prohibits the

Secretary from renewing the contract of

any PRO that is not an in-State

organization without first publishing in

the Federal Register a notice

announcing when the contract will

expire. This notice must be published

no later than 6 months before the date

of expiration, and must specify the

period of time during which an in-State

organization may submit a proposal for

the contract. If one or more qualified inState organizations submits a proposal

within the specified period of time,

HCFA may not automatically renew the

contract on a noncompetitive basis but

must instead provide for competition for

the contract in the same manner used

for a new contract. An in-State

organization is defined as an

organization that has its primary place

of business in the State in which review

will be conducted or that is owned by

a parent corporation, the headquarters

of which is located in that State.

There are currently 11 PRO contracts

with entities that do not meet the

statutory definition of an in-State

organization. The areas affected for

purposes of this notice are Alaska,

Delaware, the District of Columbia,

Idaho, Kentucky, Maine, Nebraska,

Nevada, South Carolina, Vermont, and

Wyoming.

II. Provisions of the Notice

This notice announces the scheduled

expiration dates of the current contracts

between HCFA and the out-of-State

PROs responsible for review in Alaska,

Delaware, the District of Columbia,

Idaho, Kentucky, Maine, Nebraska,

Nevada, South Carolina, Vermont, and

Wyoming. Interested in-State

organizations may submit statements of

interest to be the PRO for the

aforementioned States. The statements

must be received by HCFA no later than

June 2, 1995. In its statement of interest,

the organization must furnish materials